Targeting Iron Acquisition Blocks Infection with the Fungal Pathogens *Aspergillus fumigatus* and *Fusarium oxysporum*

Sixto M. Leal, Jr., Sanhita Roy, Chairut Vareechon, Steven deJesus Carrion, Heather Clark, Manuel S. Lopez-Berges, Antonio diPietro, Marcus Schrettl, Nicola Beckmann, Bernhard Redl, Hubertus Haas, Eric Pearlman

1 Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio, United States of America, 2 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America, 3 Department of Genetics, Universidad de Cordoba, Cordoba, Spain, 4 Department of Molecular Biology, Medical University of Innsbruck, Innsbruck, Austria

**Abstract**

Filamentous fungi are an important cause of pulmonary and systemic morbidity and mortality, and also cause corneal blindness and visual impairment worldwide. Utilizing in vitro neutrophil killing assays and a model of fungal infection of the cornea, we demonstrated that Dectin-1 dependent IL-6 production regulates expression of iron chelators, heme and siderophore binding proteins in infected mice. In addition, we show that human neutrophils synthesize lipocalin-1, which sequesters fungal siderophores, and that topical lipocalin-1 or lactoferrin restricts fungal growth in vivo. Conversely, we show that exogenous iron or the xenosiderophore defereroxamine enhances fungal growth in infected mice. By examining mutant *Aspergillus* and *Fusarium* strains, we found that fungal transcriptional responses to low iron levels and extracellular siderophores are essential for fungal growth during infection. Furthermore, we showed that targeting fungal iron acquisition or siderophore biosynthesis by topical application of iron chelators or statins reduces fungal growth in the cornea by 60% and that dual therapy with the iron chelator deferiprone and statins further restricts fungal growth by 75%. Together, these studies identify specific host iron-chelating and fungal iron-acquisition mediators that regulate fungal growth, and demonstrate that therapeutic inhibition of fungal iron acquisition can be utilized to treat topical fungal infections.

**Introduction**

*Aspergillus* and *Fusarium* are filamentous fungi that cause lethal infections in immune suppressed individuals [1,2]. Additionally, they infect the corneas of immunocompetent individuals, and are a major cause of blindness associated with ocular trauma [3,4]. Although less common, *Curvularia*, *Altenuaria*, and *Penicillium* species also cause keratitis [3]. Globally, the world health organization estimates that 1.8 million people in developing nations are blinded annually from corneal ulcers; furthermore, in developing nations, up to 65% of total corneal ulcers are caused by fungal infection, with approximately 1 million cases occurring annually in Asia and Africa [5–7].

Treatment regimens for fungal keratitis are often ineffective, with up to 60% of fungal keratitis cases requiring corneal transplantation [3]. Given the limited treatment options, there is a pressing need to develop new treatment strategies. In this effort, we recently demonstrated that inhibitors of fungal anti-oxidative responses enhanced fungal clearance in vivo and improved disease outcome [8]. As iron is essential for the redox reactions of major fungal antioxidants, including thioredoxin-dependent peroxiredoxases [9,10], and fungal iron acquisition mutants are more susceptible to oxidative stress [11], we hypothesized that targeting fungal iron acquisition may represent a potential new avenue for treatment of fungal infections.

Fungal iron acquisition primarily involves the production of hydroxamate-type siderophores that are secreted into the environment, bind iron with high affinity, and are then captured by specific siderophore receptors on the fungal cell membrane [12]. Specifically, the *A. fumigatus* siderophore biosynthesis pathway originates with the *sidA* gene, which encodes ornithine-N4-oxxygenase, resulting in conversion of ornithine to N4-hydroxyornithine [13]. Utilizing this essential precursor, the siderophore biosynthesis pathway leads to either intracellular or extracellular siderophores. The *sidC* gene product is required for production of the intracellular siderophores, ferricrocin (FC) and hydroxyferricrocin (HFC), whereas the *sidF* and *sidD* gene products are required for production of the extracellular siderophores, fusar-
Author Summary

Fungal pathogens, in addition to causing life-threatening systemic disease, can also invade the cornea and cause blindness and visual impairment. In the current study, we examined the role of iron acquisition in corneal infections caused by *Aspergillus* and *Fusarium*. We first demonstrated that expression of iron chelators, heme, siderophore binding proteins and hepcidin is elevated in infected corneas. Secondly, we showed impaired in vivo growth in *Aspergillus* and *Fusarium* with mutations in the pathway leading to production of iron-binding siderophores. These mutants were also more susceptible to killing by human neutrophils. Based on these observations, we targeted these pathways using topical iron chelators and found that they blocked fungal growth in the cornea. Finally, as statins target the enzyme HMG-CoA reductase, which is required for siderophore and ergosterol biosynthesis, we found that topical statins inhibited fungal growth and reduced infection, and showed that combined treatment with the iron chelator deferiprone and statins had an additive effect on fungal infection. Together, these studies demonstrate that therapeutic inhibition of fungal iron acquisition can be utilized to treat topical fungal infections.

inidine C (*FusC*) and triacetyllysarine C (TAFC) [13]. The *sidG* gene product is required to generate TAFC from FusC [13], whereas both the *sidH* and *sidI* gene products are required to incorporate mevalonate into the structure of extracellular siderophores [14]. As mevalonate biosynthesis is dependent on HMG-CoA reductase and this enzyme is inhibited by statins, we hypothesized that statin-mediated inhibition of fungal HMG-CoA reductase may restrict fungal iron acquisition in vivo.

Fungal siderophores are secreted into mammalian tissues during infection where they compete with host iron sequestration defenses. Under homeostatic conditions, free iron is maintained at relatively low levels by iron-binding proteins such as transferrin and ferritin [15]. In addition, mucosal secretions contain high concentrations of lactoferrin, which binds iron, and lipocalin-1, which sequesters fungal siderophores [16,17]. However, tissue damage during infection increases extracellular iron levels by releasing intracellular labile iron, ferritin, and heme-containing proteins [18]. Infection also stimulates both local and systemic immune defenses to counter microbial iron acquisition. Resident cells secrete iron-sequestering proteins and chemotactic cytokines, which recruit neutrophils to the site of infection. Neutrophils also release pre-formed and *de novo* synthesized iron sequestering proteins such as lactoferrin, Lcn-2, and the hemo-globin binding protein haptoglobin [19]. Furthermore, neutrophil-mediated oxidation is likely to increase the microbial requirement for iron to fuel iron-dependent anti-oxidative defenses. Lastly, production of cytokines such as IL-6 and IL-22 can induce local and systemic synthesis of the peptide hormone hepcidin, which degrades the iron exporter ferroportin and traps iron inside host cells [20–22].

In the current study, we examined the role of host iron sequestration and fungal iron acquisition in a murine model of *Aspergillus* and *Fusarium* corneal infection. We show that Dectin-1 and IL-6 regulate expression of genes involved in iron sequestration and that fungal growth positively correlates with serum iron levels. Using mutant *A. fumigatus* and *F. oxysporum* strains, we also demonstrate that fungal transcriptional responses to low iron levels and mevalonic acid-dependent extracellular siderophore biosynthesis, but not intracellular siderophores or reductive iron assimilation, are essential for fungal growth in *vitro* and during infection. Lastly, using iron chelators, siderophore binding proteins, and siderophore biosynthesis inhibitors including statins we provide proof-of-concept that targeting fungal iron acquisition enhances fungal clearance from infected tissues and may represent a new avenue for treatment of fungal infections.

Results

Dectin-1 and IL-6 regulate local and systemic endogenous host iron-sequestration pathways

As we previously showed that Dectin-1 mediates neutrophil recruitment into the cornea during *Aspergillus* infection [23], and IL-6 is known to mediate hepatic hepcidin production [15], we examined the role of Dectin-1 and IL-6 in iron-sequestration during fungal infection. To determine if fungal infection of the cornea initiates an iron-sequestration response, we infected C57BL/6, Dectin-1−/−, and IL-6−/− mice intrastromally with *A. fumigatus* dsRed conidia as described [8]. After 10 h, corneas were dissected and homogenized, and IL-6 was quantified by ELISA. Figure 1A shows increased IL-6 in the corneas of infected compared with naive C57BL/6 mice at 10 h post-infection; however, IL-6 was not significantly elevated in Dectin-1−/− corneas. Serum IL-6 was undetectable in naive C57BL/6 mice; however, at 24 h post-infection serum IL-6 increased to 400 pg/ml in infected C57BL/6 mice (Figure 1B). As hepcidin expression is induced by IL-6 [15], we examined hepcidin expression in livers of infected C57BL/6 and IL-6−/− mice at 24 h post-infection. Figure 1C shows that hepcidin expression was elevated 10-fold in infected compared with naive C57BL/6 mice, whereas expression was significantly lower in infected IL-6−/− mice.

During fungal infection of humans and mice, neutrophils comprise >95% of the cellular infiltrate in the cornea and are likely the predominant source of gene transcripts [23,24]. Therefore, to examining de novo transcription of iron-sequestering genes during infection we first quantified the number of neutrophils infiltrating C57BL/6 and IL-6−/− infected corneas by flow cytometry using the Ly6G NIMP-R14 monoclonal antibody. As shown in Figure 1D, there was no significant difference in neutrophil numbers between infected C57BL/6 and IL-6−/− mice. RNA was then isolated from C57BL/6 and IL-6−/− corneas at 24 h post-infection, and gene expression was measured by Q-PCR.

Compared with naive C57BL/6 corneas, expression of the iron chelating protein transferrin (TF) was up-regulated 10-fold, transferrin receptor 2 (TR2) expression was up-regulated 400-fold, and lactoferrin receptor/intelectin-1 (LR) was elevated 3-fold in infected corneas (Figure 1E). In contrast, these genes were not elevated in infected IL-6−/− corneas. Lactoferrin and transferrin receptor 1 expression were not elevated in C57BL/6 corneas, most likely due to these proteins being pre-formed in neutrophils [19].

During infection, lysed cells release heme, which microbes can utilize as a source of iron [18]. To restrict microbial access to heme, mammals produce hemopexin (Hpx) that binds to heme, and haptoglobin (HptG), which binds hemoglobin [15]. **Figure 1E** also shows that expression of Hpx and HptG in infected C57BL/6 mice is up-regulated 200-fold compared with naive mice, whereas expression is <10-fold increased in infected IL-6−/− mice.

In a low iron environment, microbial siderophores bind iron with high affinity and are subsequently internalized through siderophore transporters on the fungal cell membrane [12,25]. Humans encode lipocalin-1 (Lcn-1) and lipocalin-2 (Lcn-2), whereas mice only express Lcn-1 [26]. Both Lcn-1 and Lcn-2 target siderophores to sequester iron from microbial siderophores [19]. For example, Lcn-1 binds iron in a complex with iron-binding protein transferrin (TF) was up-regulated 10-fold, transferrin receptor 2 (TR2) expression was up-regulated 400-fold, and lactoferrin receptor/intelectin-1 (LR) was elevated 3-fold in infected corneas (Figure 1E). In contrast, these genes were not elevated in infected IL-6−/− corneas. Lactoferrin and transferrin receptor 1 expression were not elevated in C57BL/6 corneas, most likely due to these proteins being pre-formed in neutrophils [19].

During infection, lysed cells release heme, which microbes can utilize as a source of iron [18]. To restrict microbial access to heme, mammals produce hemopexin (Hpx) that binds to heme, and haptoglobin (HptG), which binds hemoglobin [15]. **Figure 1E** also shows that expression of Hpx and HptG in infected C57BL/6 mice is up-regulated 200-fold compared with naive mice, whereas expression is <10-fold increased in infected IL-6−/− mice.

In a low iron environment, microbial siderophores bind iron with high affinity and are subsequently internalized through siderophore transporters on the fungal cell membrane [12,25]. Humans encode lipocalin-1 (Lcn-1) and lipocalin-2 (Lcn-2), whereas mice only express Lcn-1 [26]. Both Lcn-1 and Lcn-2
bind to bacterial siderophores, but only Lcn-1 binds fungal hydroxamate-type siderophores [17,26]. We found that in infected C57BL/6 corneas, Lcn-2 expression is elevated 600-fold compared with 2-fold in IL-6−/− mice (Figure 1E).

Although hepcidin is produced systemically by the liver, it is also produced by neutrophils and monocytes after stimulation with IL-6, or by iron-bound transferrin-mediated activation of the transferrin receptor 2/human hemochromatosis protein (HFE) complex [15]. Further, hepcidin induction is increased synergistically by bone-morphogenetic protein (BMP)-mediated activation and signaling through a hemojuvelin/BMP receptor complex [15]. Figure 1E shows that many of the proteins involved in non-inflammatory induction of hepcidin are up-regulated at 24 h post-infection, including HFE protein (200-fold), BMP2 (200-fold), BMP-4 (30-fold), BMP-6 (10-fold), the BMP receptors: alk1 (2000-fold) alk2 (3000-fold), actr2A (300-fold), and hemojuvelin (300-fold). Interestingly, local hepcidin transcript is only 2-fold up-regulated at 24 h post-infection. In addition, ferroportin transcripts are up-regulated 250-fold during infection (Figure 1E), which may be a secondary response following hepcidin-mediated ferroportin degradation. Figure 1E shows that the transcription of all the hepcidin genes analyzed, except BMP-4, were significantly lower in infected IL-6−/− mice compared to infected C57BL/6 mice.

Lcn-1 binds to many hydrophobic molecules including phospholipids at the air-fluid interface in tears [27] . However, Lcn-1 also binds to fungal hydroxamate-type siderophores [17]. Given that human neutrophils store the bacterial-siderophore binding protein Lcn-2 in secondary granules [19], we examined if human neutrophils also produce Lcn-1. Peripheral blood neutrophils (95% purity) from three healthy human volunteers were incubated for 1 h in RPMI media in the presence or absence of Aspergillus hyphal extract, and Lcn-1 expression was examined by qPCR. Lcn-1 gene expression was detected in human neutrophils in the presence or absence of Aspergillus hyphal extract, indicating constitutive RNA expression. Taken together, results from this set of studies indicate that following fungal infection of the cornea, Dectin-1 dependent IL-6 production induces local and systemic host responses that limit microbial access to iron.
Iron availability regulates hyphal growth and the severity of *A. fumigatus* infection

Given that fungal infection initiates an iron sequestration response, we next examined if iron availability regulates fungal growth during infection. Mice were injected intraperitoneally with 5 mg Fe-dextran (90 μmole iron) or deferroxamine (5 mg), which is an iron-chelating xenosiderophore that is utilized by *A. fumigatus* [28]. Twenty four hours after the last injection, GFP-expressing *A. fumigatus* (Af-dsRed) conidia were injected into the corneal stroma of C57BL/6 mice [8,23]. After 24 h, total serum iron was quantified in treatment and control groups.

**Figure 2A** shows that serum iron levels in infected mice were reduced 2-fold compared with naive mice, indicating systemic iron-sequestration during inflammation [15]. In contrast, mice given systemic Fe-dextran, but not deferroxamine had significantly elevated serum iron compared to vehicle-treated mice. Despite the difference in serum iron levels, **Figures 2B**, **C** show that whereas fungal mass (dsRed) increases over 48 h in vehicle-treated mice, this was significantly higher in Fe-dextran and deferroxamine-treated mice. Consistent with these data, **Figure 2D** shows that at 48 h post-infection, CFU were significantly higher in Fe-dextran and deferroxamine-treated mice compared with control, vehicle-treated mice. As filamentous fungi grow by hyphal extension and not cell division, the dsRed measure of fungal mass increases over time, whereas CFU decreases from the initial inoculum [15]. **Figures 2B**, **E**, and **F** show that corneal opacification was also increased in Fe-dextran and deferroxamine-treated mice compared to vehicle-treated mice, consistent with increased fungal growth. The increased fungal growth in deferroxamine treated mice is likely due to its xenosiderophore function, which can be used by *Aspergillus* for iron acquisition [28].

To examine the effect of limiting iron availability during infection, C57BL/6 corneas were infected with *A. fumigatus* dsRed conidia as described (12), and the iron chelating protein lactoferrin was added topically (10.4 μg in 5 μl) at 0 h and 6 h post-infection. As shown in **Figures 2G–I**, infected corneas given topical lactoferrin had significantly less fungal mass (dsRed) and CFU per eye at 24 h post-infection compared with those given vehicle alone. Taken together with results from Fe-dextran and deferroxamine-treated mice, these studies demonstrate that fungal growth in the cornea is dependent on increased free iron or bio-available iron.

Siderophores and detection of low iron concentrations but not reductive iron assimilation is required for fungal growth during infection

Given that fungal growth during infection is enhanced by the exogenous xenosiderophore deferroxamine, we next examined the role of endogenous fungal siderophores using *A. fumigatus*, *F. oxysporum*, and *Alternaria brassicicola* iron acquisition mutants. The *A. fumigatus* ΔsidA mutant does not synthesize extracellular or intracellular siderophores [29], whereas the ΔhapX strain lacks the transcription factor HapX that is activated by low iron concentrations, and which regulates expression of genes involved in iron acquisition including siderophores and repression of iron-dependent pathways [30].

**Figure 3A** shows no significant difference in fungal growth in media alone between the parent (WT) strain and the ΔsidA and ΔhapX mutants, indicating that there is no effect of these mutations on fungal growth in the presence of an exogenous source of iron. We next examined the growth of the WT strain and the ΔsidA and ΔhapX mutants in the presence of neutrophils, which we recently showed kill hyphae by producing reactive oxygen species [8]. Conidia (spores; 12,500) were cultured 4–6 h in SDB media to allow germination and production of hyphae and incubated with 1 × 10⁶ neutrophils. In contrast to RPMI media alone in which all strains grew equally, in the presence of human neutrophils, growth of the ΔsidA and ΔhapX mutants was significantly less than the WT parental strain (Figure 3A), indicating that adaptation to iron starvation and siderophores, which requires SidA and HapX is essential for survival in the presence of neutrophils.

Consistent with a role for these genes in virulence, we found that at 48 h post-infection, corneas infected with the *A. fumigatus* mutant strains ΔsidA or ΔhapX had significantly lower CFU compared with the parent strain (Figure 3B). **Figure S1** shows that corneas infected with the complemented ΔsidA sidAΔR or the complemented ΔhapX hapXΔR, show no significant difference in opacification or CFU as the WT parental strain. In contrast, although the ΔfrtA mutant lacks a membrane-bound iron transport channel protein and is therefore deficient in cellular uptake of environmental iron [29], there was no significant difference in CFU in this mutant, indicating that this transporter protein is not essential for fungal growth *in vivo*. Similarly, **Figures 3C, E, and F** show that mice infected with the ΔsidA or ΔhapX mutants have significantly less corneal opacification than the parent *A. fumigatus* strain, whereas the ΔfrtA mutant was not significantly different. Histological analysis shows a pronounced cellular infiltrate and fungal hyphae in the corneas of mice infected with the parent strain, whereas no hyphae were detected in ΔsidA infected corneas, indicating that these mutants did not germinate in the cornea (Figure 3D). As with *A. fumigatus*, mice infected with the *F. oxysporum* ΔhapX strain also exhibit significantly lower CFU than the parent strain at 48 h post-infection (Figure 3G, and *A. brassicicola* siderophore mutants have significantly less CFU than the parent strain (Figure S2). **Figure 3H–J** demonstrate that mice infected with the *F. oxysporum* ΔhapX strain also exhibit significantly less corneal opacification compared to the parental strain. **Figure S1** shows that corneas infected with the Fusarium complemented ΔhapX strain hapXΔR show no significant phenotypic differences from the WT parental strain. Taken together, these data indicate that siderophores have a critical role in fungal growth during infection, whereas reductive iron assimilation is not essential.

Extracellular siderophores are required for fungal infection

To determine the relative contribution of intracellular versus extracellular siderophores in fungal keratitis, corneas were infected with the ΔsidF and ΔsidC mutants. **Figure 4B** shows that CFU from corneas infected with the ΔsidF mutant that leads to extracellular siderophore production was significantly lower than those infected with WT *A. fumigatus*, having a similar CFU as ΔsidA mutants. In contrast, ΔsidC mutants that regulate production of intracellular siderophores were not significantly different from the parent strain. Consistent with this finding, corneas infected with ΔsidF had significantly lower cornea opacity area and intensity values compared with mice infected with WT *A. fumigatus*, whereas ΔsidC mutants were not significantly different (Figure 4C–E). Together, these findings indicate that extracellular, but not intracellular siderophores are essential for fungal growth in the cornea and development of keratitis.

To determine the relative contribution of the extracellular siderophores FusC and TAFG, we infected corneas with ΔsidD mutants, which do not produce extracellular siderophores, or with ΔsidG mutants, which produce FusC but not TAFG, and compared them with the parent *A. fumigatus* strain that produces both FusC and TAFG [13]. **Figure 4B** shows that mice infected
with ΔsidD mutants had significantly lower CFU compared with WT *A. fumigatus*, whereas ΔsidG were not significantly different. Corneal opacification scores reflected the CFU data, with ΔsidD but not ΔsidG mutants having significantly less opacification than WT *A. fumigatus* (Figure 4C–E). These findings indicate that sidD-mediated synthesis of FusC rather than sidG-mediated synthesis of TAFC is necessary and sufficient to support fungal growth in vivo. Figure S1 shows that corneas infected with the complemented strains sidD<sup>R</sup> and sidG<sup>R</sup> show no phenotypic differences from the WT parental strain. Figure S2 shows that both intracellular and extracellular siderophore mutants of *Alternaria brassicicola* also have impaired growth during infection. Together, these data clearly demonstrate that extracellular siderophores are essential for both *Aspergillus* and *Alternaria* growth during tissue infection, and that even though TAFC is reportedly more stable [13], FusC production is sufficient to maintain fungal growth in vivo.

Mevalonate incorporation into extracellular siderophores is required for fungal infection

Fungal extracellular siderophore biosynthesis requires HMG-CoA reductase-dependent synthesis of the precursor mevalonate [14]. The *Aspergillus* genes *sidD* and *sidH* encode a CoA-ligase and an enoyl-CoA-hydratase, respectively, which convert mevalonic acid to anhydromevalonyl CoA and incorporate this precursor through the sidF-D-G pathway into the structure of fusarinine C and TAFC (Figure 5A) [13,14].

Figure 2. The effect of iron dextran, deferoxamine and lactoferrin on *A. fumigatus* corneal infection. A. Serum iron levels 24 h after corneal infection. C57BL/6 mice were pre-treated at day -2, and day-1 with I.P. injections of iron-dextran (Fe-Dextran) or deferoxamine (Defox), and serum iron levels were measured by spectrophotometry (data are mean ± SD of 5 mice per group). B. Fungal growth (dsRed *A. fumigatus*) and corneal opacity in mice given Fe-Dextran or Defox. C. Metamorph image analyses of dsRed fluorescence. D. Colony forming units (CFU) per eye at 4 h and 48 h post-infection E,F. Metamorph image analyses of percent (E) and total (F) corneal opacification. G–I: Effect of lactoferrin on fungal growth. C57BL/6 mice were infected with *A. fumigatus* dsRed conidia, and given topical lactoferrin (10.4 μg) at 0 and 6 h post-infection. Corneas were examined after 24 h. G: representative images; H. image analysis of dsRed expression, and I. CFU per eye. Panels B and G show representative images, and data points in panels C–F, H, I represent individual corneas. All panels show representative data from one experiment except for panels D and I which show pooled data from repeat experiments. These experiments were repeated three times with similar results. doi:10.1371/journal.ppat.1003436.g002
To determine if this pathway is essential for fungal growth during tissue infection, C57BL/6 mice were infected with A. fumigatus mutant strains \( \Delta sidH \) and \( \Delta sidI \) and examined as before. Figure 5B shows that mice infected with \( \Delta sidH \) or \( \Delta sidI \) exhibit significantly less CFU than mice infected with the WT strain, indicating that mevalonate incorporation into extracellular siderophores is essential for fungal growth during tissue infection. Further, mice infected with either \( \Delta sidH \) or \( \Delta sidI \) exhibit...
significantly less cornea opacity at all time-points compared to mice infected with WT *A. fumigatus* (Figure 5C–E). Figure S1 shows that corneas infected with the complemented ΔsidH strain sidH<sup>R</sup> or the complemented ΔsidI strain sidI<sup>R</sup> show no significant difference in opacification or CFU as the WT parental strain.”

**Lipocalin-1 sequesters fungal siderophores and restricts fungal growth during infection**

Humans produce two lipocalins with siderophore binding activity [26]. Lipocalin-1 (Lcn-1) binds to a wide range of bacterial and fungal hydroxamate-type siderophores [17], whereas Lcn-2 binds catechol-type bacterial siderophores but not fungal siderophores [31,32]. We therefore examined the role of Lcn-1 on *A. fumigatus* using the same assays as above. Figure 6B shows significantly less fungal growth incubated with 40 μg/ml or 4 μg/ml Lcn-1 than in RPMI alone, and that growth of *A. fumigatus* in the presence of neutrophils and 4 μg/ml Lcn-1 was significantly less than with neutrophils alone or Lcn-1 alone. Figures 6C–E show significantly less fungal dsRed and CFU in mice given topical Lcn-1 (16 μg/8 μl) at 0 h and 6 h after infection compared with infected mice not given Lcn-1. These findings indicate that topical Lcn-1 inhibits fungal growth *in vivo*, presumably by sequestering fungal siderophores.

**Topical simvastatin and deferiprone inhibit fungal infection**

As shown in Figure 5, *Aspergillus* SidII and SidH proteins incorporate mevalonate into the structure of extracellular siderophores and are essential for fungal growth in the cornea. Also, HMG-CoA reductase is required for mevalonate production and can be targeted by statins to inhibit siderophore biosynthesis [14,33] (Figure 7A). To determine the effect of blocking this
pathway on fungal growth, *A. fumigatus* and *F. oxysporum* were incubated with the HMG-CoA reductase inhibitors simvastatin and lovastatin, or with the iron chelators deferiprone and deferoxamine.

As shown in Figure 7B, there was significantly less growth of *A. fumigatus* following 16 h incubation in SDB media with simvastatin, lovastatin and deferiprone, but not deferoxamine, thereby demonstrating a direct effect of statins and deferiprone on fungal growth. Similar results were obtained with *Fusarium oxysporum* (Figure 7C). Interestingly, a statin dependent dose curve was observed with *A. fumigatus* when exposed to simvastatin or lovastatin (Figure 7B), however, a dose curve was only observed when *Fusarium* was treated with simvastatin not lovastatin (Figure 7C). This observation likely reflects differences in the pharmacokinetics of different statins and their ability to penetrate into the fungal cytoplasm and inhibit HMG-CoA reductase of multiple fungal genera and species [33].

To ascertain if these agents enhance fungal sensitivity to killing by neutrophils, *A. fumigatus* conidia were cultured with the HMG-CoA reductase inhibitors simvastatin and lovastatin, or with the iron chelators deferiprone and deferoxamine.

As shown in Figure 7B, there was significantly less growth of *A. fumigatus* following 16 h incubation in SDB media with simvastatin, lovastatin and deferiprone, but not deferoxamine, thereby demonstrating a direct effect of statins and deferiprone on fungal growth. Similar results were obtained with *Fusarium oxysporum* (Figure 7C). Interestingly, a statin dependent dose curve was observed with *A. fumigatus* when exposed to simvastatin or lovastatin (Figure 7B), however, a dose curve was only observed when *Fusarium* was treated with simvastatin not lovastatin (Figure 7C). This observation likely reflects differences in the pharmacokinetics of different statins and their ability to penetrate into the fungal cytoplasm and inhibit HMG-CoA reductase of multiple fungal genera and species [33].

To ascertain if these agents enhance fungal sensitivity to killing by neutrophils, *A. fumigatus* conidia were cultured with the HMG-CoA reductase inhibitors simvastatin and lovastatin, or with the iron chelators deferiprone and deferoxamine. As shown in Figure 7C, fungal growth was significantly less when incubated with neutrophils and simvastatin, lovastatin, and deferiprone compared with neutrophils alone, whereas there was no significant difference in the presence of deferoxamine. The inhibitory effect of 1 μM statins on fungal growth shown in panel B was not observed in this assay, most likely due to siderophore production during the 4–6 h growth in the absence of statins.

To ascertain if statins can restrict fungal growth during infection, mice were infected intrastromally with *A. fumigatus*, and given topical simvastatin, deferiprone, or deferoxamine at the time of infection and after 6 h. At 24 h post-infection, mice eyes were imaged for corneal opacity and fungal dsRed, and processed for fungal CFU. Importantly, unlike prior experiments, which examined CFU at the 48 h time-point, at 24 h CFU in infected eyes does not decrease unless treated with anti-microbial agents. Therefore, in this 24 h assay and unlike prior experiments, vehicle-treated CFU do not decrease but instead represent the maximum fungal CFU value per assay. As shown in Figure 7E and F, mice treated with simvastatin or deferiprone exhibited significantly less fungal mass compared to vehicle-treated mice, which was further decreased when given both compounds. Conversely, mice given simvastatin together with deferoxamine had significantly higher fungal mass than mice given simvastatin alone, indicating that exogenous deferoxamine counters the inhibitory activity of statins. Figure 7G shows similar responses when CFU were measured 24 h post-infection, with significantly less CFU in mice given simvastatin, deferiprone or both, and partial reversal of the inhibitory effect of simvastatin when mice also received topical deferoxamine, indicating that simvastatin is targeting siderophore biosynthesis in addition to ergosterol synthesis in vivo. Mice treated with deferoxamine alone showed elevated fungal mass (Figure 7E) compared with vehicle-treated mice, but at this time point, CFU values were not significantly different from vehicle-treated mice (Figure 7F). Taken together, these findings clearly demonstrate that topical statins and iron chelation can block fungal growth during infection.

**Discussion**

Previous work in our laboratory demonstrated that fungal anti-oxidative responses are essential for survival during tissue infection, and that fungal growth can be inhibited in vivo by
targeting fungal thioredoxin [8]. As thioredoxin-regulated peroxiredoxases, catalases, and other antioxidants require iron to quench reactive oxidants [9,34], the current study examined the role of host iron sequestration and fungal iron acquisition during infection. In examining endogenous iron levels, we found a two-fold reduction in serum iron levels following fungal infection which correlated with elevated expression of iron-chelating proteins, heme-binding and siderophore-sequestering proteins in infected corneas, and systemic induction of hepatic hepcidin. Expression of these iron-sequestering proteins was dependent on Dectin-1, which we and others showed is important in recognizing β-glucan on germinating conidia [23,35,36]. Expression of these proteins was also dependent on IL-6, which has been shown to induce liver hepcidin and reduce systemic iron levels [15].

In this iron-restricted environment, we show that fungal siderophores are essential for microbial growth and survival. This notion is supported by our findings that siderophore mutants are unable to grow in the cornea, and that exogenous iron chelators or inhibitors of fungal siderophore biosynthesis impair fungal growth both in vitro when incubated with human neutrophils, and in vivo in a murine model of fungal infection. Given that the siderophore biosynthesis pathway is highly conserved in filamentous fungi [12], our findings are very likely relevant to fungal infections of other tissues in addition to other fungal pathogens. **Figure 8** illustrates the fungal siderophore biosynthesis pathway and highlights the key findings in this study.

Firstly, we identified that both *Aspergillus* and *Fusarium* require the transcription factor HapX to sense and respond transcriptionally to low iron levels and survive during infection. Further, we show that *A. fumigatus* strains ΔsidF, ΔsidD, ΔsidH, or ΔsidI, that do not express the extracellular siderophores are attenuated during infection of the cornea, whereas based on the absence of a phenotype with ΔsidC mutants, there is no apparent role for intracellular siderophores. We show that production of extracellular siderophores is also required for infection with *Alternaria*. These findings are consistent with an essential role for HapX and extracellular siderophores during experimental *A. fumigatus* lung infection [11,14,30], the requirement of HapX for *Fusarium* infection of tomato plants and immunosuppressed mice [37], and the requirement of siderophores for *Alternaria* infection in maize [38]. Interestingly, iron starvation also activates the transcription factor AcuM, which increases HapX expression and down-regulates the iron-repressing transcription factor SreA, resulting in fungal iron acquisition [39]. The role of AcuM and SreA during corneal infection has yet to be determined.

In the present study, we also examined the potential for statins to inhibit fungal HMG-CoA reductase, which is required for mevalonic acid production and extracellular siderophore biosynthesis [14]. Consistent with a report on pulmonary aspergillosis [14], we used mutants to demonstrate that SidI and SidH-dependent mevalonic acid incorporation into extracellular siderophores is essential for infection of the cornea. Further, we show that simvastatin and lovastatin inhibit fungal growth in vitro, and also enhance growth inhibition by human neutrophils. Consistent with the difference in statin activity in treating hypercholesterolemia [40], simvastatin exhibited 10-fold greater inhibitory activity...
than lovastatin in restricting fungal growth in vitro. During infection, topical application of simvastatin inhibited fungal growth that was only partially reversed by exogenous siderophores, indicating that statins function in vivo by inhibiting both fungal siderophore and ergosterol biosynthesis. The fungicidal activity of statins has been reported for *Aspergillus*, *Fusarium*, *Mucorales*, and *Candida* [41–43]. However, to our knowledge, this is the first study to clearly demonstrate a therapeutic effect of statins in an experimental fungal infection. In contrast to systemic statin treatment, topical application is likely to have minimal risk of side effects [33]. Future studies will examine if statins can restrict fungal growth at later stages of infection.

In addition to showing inhibition of siderophore biosynthesis, the current study demonstrates that exogenous lipocalin-1 impairs fungal growth in the presence of human neutrophils and during infection. This finding is consistent with the reported role for Lcn-1 in sequestering fungal siderophores, including TAFC [17]. The affinity of Lcn-1 for fungal siderophores is similar to that of fungal siderophore receptors [17], and therefore at high concentrations Lcn-1 could sequester siderophores from fungal receptors. Further, it is likely that Lcn-1-siderophore complexes are internalized through the lipocalin-interacting membrane receptor (LIMR) resulting in siderophore degradation [44,45]. Endogenous Lcn-1 is abundant in human tears (3 mg/ml), nasal mucosa, and tracheal

Figure 7. Effect of topical simvastatin and deferiprone on fungal infection. A. Statin targeting of fungal HMG-CoA reductase in siderophore biosynthesis. B, C. Effect of statins and iron chelators on growth of *A. fumigatus* and *F. oxysporum* in vitro. B. Simvastatin, lovastatin, deferiprone, or deferoxamine were added to growing cultures of *A. fumigatus* or *C. F. oxysporum* for 16 h, and hyphal growth was quantified by calcofluor white. D. Growth of *A. fumigatus* incubated with these compounds in the absence (black bars) or presence (gray bars) of human neutrophils by calcofluor white quantification (data are mean +/- SD of five replicate wells) E. C57BL/6 mice were infected with *A. fumigatus* and at 0 and 6 h post-infection 13.4 μg of simvastatin (Sv), deferiprone (11.1 μg), deferoxamine (52.5 μg), Sv + deferiprone, or Sv + deferoxamine was applied topically to infected corneas and eyes were imaged at 24 h post-infection. F. Metamorph image analysis was used to quantify fungal dsRed expression and G. eyes were homogenized for CFU analysis. B–D: data are mean +/-SD of five replicate wells; F,G: data points represent individual corneas. All panels show representative data from one experiment except for panel G which shows pooled data from repeat experiments. Similar results were found in three repeat experiments. Abbreviations: HMG-3-hydroxy-3-methyl-glutaryl-CoA, Sv-simvastatin, Lv-lovastatin, Dprone-deferiprone, Defox-deferoxamine.

doi:10.1371/journal.ppat.1003436.g007
secretions where it can function prophylactically to prevent mucosal fungal infections [17,46]. However, as we now show that human neutrophils express Lcn-1, it is possible that Lcn-1 also has a protective role during active infection.

In addition to targeting siderophores, we showed that reducing local tissue iron concentrations by topical application of the iron chelating protein lactoferrin restricts fungal growth in vivo. This finding is consistent with the reported role for lactoferrin in blocking conidia germination in vitro by human neutrophils [47], and suggests that in vivo, neutrophil-derived lactoferrin restricts the growth of conidia and hyphae by binding free iron. Given that siderophores exhibit a higher affinity for iron than lactoferrin [12], it is likely that fungal siderophores can acquire iron from lactoferrin during infection; however, the rate of siderophore iron acquisition in a lactoferrin-rich environment is likely slower than in the absence of lactoferrin given the scarcity of free iron or iron-bound to lower affinity biomolecules.

Similarly, we showed that the iron chelator deferiprone sensitizes fungi to human neutrophils and blocks fungal infection. However, deferiprone is also a very small molecule (MW = 140 g/mole), approximately 600-fold smaller than lactoferrin, and is therefore released from tissues more readily than lactoferrin, resulting in both iron sequestration and depletion from infected tissues [48]. Deferiprone has been used effectively and safely to lower iron levels in patients with hemochromatosis [48], and although widely utilized in Europe, it is not currently licensed in the USA. Importantly, deferiprone, unlike deferoxamine, is not a xenosiderophore [28] and is not associated with an increased risk of fungal and bacterial infections [49–57].

Iron chelators have been used to treat *Aspergillus* and *Rhizopus* infections in mice [57–60], and a clinical trial examined the potential of the iron chelator deferasirox to enhance the efficacy of liposomal amphotericin B to treat mucormycosis (the DEFEAT Mucor study). However, the trial was unsuccessful due to an unexpected increased risk of death in patients receiving deferasirox adjunct therapy [61]. The DEFEAT Mucor study exhibited a limited sample size and imbalanced stratification of the sickest patients into the deferasirox treatment group and may not accurately reflect the potential of deferasirox to treat mucormycosis. However, systemic deferasirox treatment does cause side effects that include agranulocytosis and nephrotoxicity [62]. In the current study, we demonstrated that local (topical) application of iron chelators is both effective in inhibiting fungal growth and preventing corneal disease. As local administration is highly unlikely to cause systemic side effects, clinical studies using topical iron chelators and fungal iron acquisition inhibitors are unlikely to cause adverse reactions, especially if combination therapies targeting iron acquisition can use low drug concentrations. This approach could be used to treat fungal infections not only in the cornea, but also in other tissues that could be treated topically such as the tongue, skin, and nails.

In conclusion, we have identified host iron sequestration and fungal siderophore biosynthesis as essential mediators of fungal growth during infection. One approach to exploiting these findings is to chelate local iron at the infectious site utilizing deferiprone or lactoferrin. A second approach is to inhibit the ability of fungi to acquire iron utilizing the siderophore-binding protein Lcn-1 or the
siderophore biosynthesis inhibitor simvastatin. However, the most efficacious strategy would likely involve the combination of iron chelation and inhibition of siderophore biosynthesis. In this study, we provide proof-of-concept that dual treatment with deferriprone and simvastatin further restricts fungal growth during infection. As both deferriprone and simvastatin have a long history of safe use in patients, it is possible that these agents can be successfully utilized to treat a broad range of fungal infections.

Materials and Methods

Use and source of animals

All animals were treated in accordance with the guidelines provided in the Association for Research in Vision and Ophthalmology ARVO statement for the Use of Animals in Ophthalmic and Vision Research, and were approved by Case Western Reserve University IACUC. C57BL/6 mice (6-12 wk old) and IL-6-/- mice were kindly provided by Dr. Yoichiro Iwakura (University of Tokyo; Tokyo, Japan).

Fungal strains and growth conditions

Table 1 lists the genotype and phenotype of all strains utilized in this study. Aspergillus fumigatus was cultured on Vogel’s minimal medium (VMM) +2% agar and Fusarium oxysporum lycopersici was cultured on potato dextrose agar (PDA); Alternaria brassicicola was cultured in complete media as described previously [30]. All solid media used in this study were supplemented with 10 mM FeSO₄ to enhance conidia production by siderophore mutants. For neutrophil-fungus incubation assays, all fungi were grown in RPMI media w/o FeSO₄ supplementation. The Alternaria brassicicola Δnps2, Δnps6, and Δnps2/6 strains were kindly provided by Dr. B. Gillian Turgeon (Cornell University, Ithaca, NY).

Mouse model of Aspergillus and Fusarium keratitis

Aspergillus and Fusarium strains were cultured as described above for 2–3 days, and fresh conidia were disrupted with a bacterial L-loop, harvested in 5 ml PBS, and filtered through sterile PBS-soaked cotton gauze in a 10 ml syringe to obtain pure conidial suspensions. Conidia were quantified using a hemocytometer and adjusted in PBS to a final stock solution of 15–20,000 conidia/μl. Mice were anesthetized with 1.25% 2, 2, 2-tri-bromoethanol in 1 ml PBS, using the Mixer Mill MM300 (Retsch) at 33 Hz for 4 min. Subsequently, 100 μl aliquots were plated onto bacterio-logic-grade Sabouraud dextrose agar plates, incubated for 24 h at 37°C (Aspergillus) or at 30°C (Fusarium and Alternaria), and the number of CFU/eye was determined by direct counting. The weight of the whole eye is consistent from one mouse to the next regardless of infection, and as we homogenize the entire eye and not just the cornea, we calculate CFU from the entire eye not just a representative sample. Fungal dsRed and CFU analysis do not have a linear correlation as hyphae of varying lengths show differences in dsRed fluorescence, but are still counted as a single CFU. Also, as homogenization can potentially damage branched hyphae, which may be more abundant in wild type compared with mutants, we may be underestimating the difference in CFUs between strains. All CFU graphs show pooled data from at least three repeat experiments.

Quantification of IL-6 protein in mouse corneas and serum

Corneas were homogenized in 150 μl reagent diluent (R & D Systems, Minneapolis, MN) using the Retsch MM 300 ball miller at 33 Hz for 4 min (Qiagen). Mouse serum was obtained as described below and assayed directly. IL-6 protein was quantified using a mouse IL-6 ELISA kit as per manufacturer’s instructions (R & D Systems, Minneapolis, MN).

Quantification of neutrophils in mouse corneas

Corneas were dissected, cut into 8 small fragments, and incubated in 80 units of collagenase (Sigma-Aldrich) for 1–2 h. The cell suspensions were filtered, centrifuged at 300*g for 5 min at 4°C and washed in FACS buffer (PBS+1% FBS+0.5% Na azide). Cells were then incubated with anti-mouse CD16/32 antibody (Fc block, clone 93, eBioscience) for 10 min followed immediately by incubation with biotinylated rat anti-mouse NIMP-R14 or isotype-control for 45 min. Cells were washed and incubated with streptavidin-PE-Cy7 for 30 min in the dark. Cell suspensions were then analyzed utilizing a C6 Accuri flow cytometer with gates set based on isotype controls.

Quantitative PCR of infected corneas

C57BL/6 mice and IL-6-/- mice were infected with A. fumigatus strain Af-dsRed as described above. At 24 h mice were sacrificed, corneas were excised, suspended in tissue lysis buffer (Qiagen, Valencia, CA) and homogenized using the Mixer Mill MM300 (Retsch) at 33 Hz for 2 min. Subsequently, RNA was extracted from samples using RNeasy mini kit according to the manufacturer’s directions (Qiagen, Valencia, CA). Samples with a 260/280 (RNA:protein) ratio of 2.0 were used to generate cDNA using the superscript first strand synthesis system (Life technologies, Grand Island, NY) using standard methods. Real Time PCR was performed on the cDNA samples using the SYBR green...
system (Applied Biosystems, Carlsbad, CA). All primers used in this study are listed in Table 2 and were synthesized by Integrated DNA technologies (San Diego, CA). Fold change with respect to naïve uninfected corneas was calculated using the $2^{\Delta \Delta CT}$ method. Data are therefore presented as fold increases of relative gene expression (log (RQ)). RT-PCR samples were also analyzed by 2% agarose gel electrophoresis.

Quantification of iron content in mouse serum

Whole blood was obtained from mice by retro-orbital bleeding, and serum was recovered following blood coagulation. An iron assay kit (ABCAM, Cambridge, MA) was subsequently used to quantify Fe$^{2+}$ and Fe$^{3+}$ in the serum using manufacturer’s instructions. Briefly, 25 μl of serum was added to 75 μl iron assay buffer and 5 μl iron reducer, which reduces Fe$^{3+}$ to Fe$^{2+}$. Next, 100 μl of the iron-probe solution was added yielding a Fe$^{2+}$-ferene S complex that absorbs light at 593 nm. Spectrophotometry was used to detect absorbance at this wavelength.

In vitro human neutrophil:hyphae growth inhibition assay

Human neutrophils were isolated from normal, healthy donors using Ficoll-Paque Plus (GE) density centrifugation as described [8]. Isolated conidia from each A. fumigatus mutant were cultured in 200 μl SDA media (12,500/well) in black-wall 96 well plates with an optically clear bottom (Gostar 3720) until early germ tubes were observed (4–6 h). Wells were washed twice with sterile ddH$_2$O and incubated 16 h with either RPMI media (+ Control), PBS (− Control), or human peripheral blood neutrophils suspended in RPMI at 0.5–1*10$^5$/well, which we know does not inhibit fungal growth [8]. After 16 h incubation, plates were washed and stained with 50 μl calcofluor white stain, which binds chitin (Fluka 18909) for 5 min in the dark. Subsequently, plates were washed three times with ddH$_2$O and quantified by fluorometry (360/440 nm; Synergy HT; Biotek). In assays where no neutrophils were added, fungi were incubated in SDA media alone with or without inhibitors. Fungi cultured in 96-well plates exhibit maximal growth by 16 h; therefore, this assay measures only relative decreases in fungal growth.

Statistical analysis

Statistical analysis was performed for each experiment using one way ANOVA with a Tukey post-hoc analysis using Prism software (GraphPad Software Inc, La Jolla, CA). A p value $< 0.05$ was considered significant.

Ethics statement

All animals were treated in accordance with the guidelines provided in the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.
| Primer | Source (PB ID) | Sequence | Protein Function |
|--------|---------------|----------|-----------------|
| **Iron Chelation** | | | |
| Lactoferrin | 141803548b2 | CCGCTCAGTTGTGCTAAGAAA | Binds Fe at low pH |
| | | CATGGCATCAGCTTGTTTG | |
| Transferrin | 118129942b1 | GCTGTCCTGACAAACGGT | Binds Fe at neutral pH |
| | | GGTATTCTCCTGCTGACAC | |
| Tf receptor 1 | 291045184b1 | GATCAAGCAAGACAGATTCTC | Internalizes transferrin |
| | | GTGATGCAAAATGCTCCCAAC | |
| Tf receptor 2 | 113204629b1 | CCGTGGGGCTACTTCCGAGA | Internalizes transferrin |
| | | AGATGGTCTGAGAGGTTCTG | |
| Lf receptor/intelectin 1 | 118130045b1 | CAGCACCAGGACATACTGTG | Internalizes lactoferrin |
| | | TCCCTTGCTGATTTCCAATGG | |
| Lipocalin-1: Human | 32455234b1 | ATGTGTTAGGGACGATGTAGTC | Binds fungal siderophores |
| | | CGATTCAGATAGTTACGG | |
| **Heme Binding Protein** | | | |
| Haptoglobin | 254910958b1 | GCACCTGTCCTGTAGCTGCT | Binds hemoglobin |
| | | GCCGCTAGTTGATAGACCT | |
| Hemopexin | 160358828b1 | AGACGTGCCAATAATCTCCT | Binds heme |
| | | CAACCTTCCGGTTCGAGTA | |
| **Siderophore Binding** | | | |
| Lipocalin-1 | 32455234b | ATGTGTCAGGGACGATGTAGTC | Binds fungal siderophores |
| | | CGATTCAGATAGTTACGG | |
| Lipocalin-2 | 34328048b1 | GCAGGTGGTACGTTGTGGG | Binds bacterial siderophores |
| | | CTCTTGTAGCTCATAGATGGTG | |
| **Hepcidin Signaling** | | | |
| Interleukin 6 | 13624310b1 | CTGCAGAAGACTTCCATCCAG | Induces HAMP* synthesis |
| | | AGTGTTAGTACAGCAGTGG | |
| HFE | 145966687b1 | CCGGCTGCCCTTGTTTGA | Signal transduction→HAMP |
| | | CTGCTCCTGGTGTGCTCT | |
| BMP-2 | 71896668b1 | TCTCCTGGGAAGATACAGGA | Amplifies HAMP synthesis |
| | | TGGTCTCAAGATCTGTCAAG | |
| BMP-4 | 121949822b1 | ATTCCTGTGAAACGAATGCTG | |
| | | CGATTCAGATAGTTACGG | |
| BMP6 | 118131176b1 | GCCGGGATGCAAAGGGAGAT | |
| | | ATGGGACAGGCGGGTGGTGA | |
| alk1- BMPR type 1a | 133891829b1 | TCGTACATTGGAATACAGAC | BMP* receptor |
| | | CAAGGTATCCTCTGTGGCTATA | |
| alk2-BMPR type 1b | 41053831b1 | CCTCGGGCAAGATCTCCTAC | |
| | | CCTAGACATCCAGAGTGGACA | |
| actRIa-BMPR type 2 | 145966831b1 | GTTATGTTGCTGTTGGAGAAAT | |
| | | AAAGGCGGTACGTTCCATCTG | |
| Hemojuvelin | 166295197b1 | ATGGGCGTGCCCCATGTC | BMPR signaling |
| | | CAGCCGGAGATTCTGCAC | |
| Hepcidin | Blood 2010 [63] | CTGAGCAGCCACACCTACTC | Degrades ferroportin |
| | | TGGTCCTAGGGTGATTTTGG | |
| Ferroportin | 124248584b1 | TGGACTATGGAAGACAGCCT | Exports iron from cells |
| | | TGGCATCTTATCACCCAGT | |
| **Housekeeping gene** | | | |
| β-actin- Mouse | 6671509a1 | GGCCTGATCCCTCCCTCTACG | Housekeeping gene |
| | | CAGGTGGTAAACATGCGCATGT | |
mology ARVO statement for the Use of Animals in Ophthalmic and Vision Research, and were approved by Case Western Reserve University IACUC (2011-0063). The protocol for the use of human peripheral blood from normal healthy volunteers was approved by the Institutional Review Board at University Hospitals of Cleveland (07-11-21). Informed consent was obtained in writing from each volunteer.

Supporting Information

Figure S1 Complementation of *A. fumigatus* and *F. oxysporum* mutant strains causes phenotypic reversion to WT parental strain phenotypes. *A. fumigatus* C57BL/6 mice were infected with 40,000 conidia from the WT *A. fumigatus* strain ATCC 46465 and the two complemented strains: sidAR, sidR, and the complemented strains: C57BL/6 mice were infected with 30,000 conidia from the WT *F. oxysporum* strain 4287 and the complemented strain hapXR and CFU analysis was performed at 48 h post-infection. *B. C57BL/6* mice were infected with 50,000 conidia from the isogenic mutant strains: *D. Alternaria brassicicola* with 40,000 conidia from the WT parental strain phenotypes. *A. fumigatus* mutant strains causes phenotypic reversion to WT parental strain phenotypes. *A. fumigatus* infected eyes were imaged at 24 h and 48 h post-infection. *C. A. fumigatus* and *D. F. oxysporum* infected eyes were imaged at 24 h and 48 h post-infection.

(TIFF)

Acknowledgments

We would like to thank Dr. B. Gillian Turgeon for helpful discussions and the CWRU visual sciences core facility managers for outstanding technical assistance.

Author Contributions

Conceived and designed the experiments: SML EP HH. Performed the experiments: SML SR SdC CV HC. Analyzed the data: SML EP HH. Contributed reagents/materials/analysis tools: MSLB MS HH BR NB AdP. Wrote the paper: SML EP.

References

1. Milner JD, Sandler NG, Dowek DC (2010) Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections. Curr Opin HIV AIDS 5: 179–185.
2. Antachopoulos C (2010) Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect 16: 1335–1342.
3. Thomas PA (2003) Fungal infections of the cornea. Eye 17: 852–862.
4. Gosner EW, Keay LJ, Ochlicher RA, Iwcover A, Allenso EG, et al. (2010) Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology 117: 2263–2267.
5. World Health Organization (October 2011) Visual Impairment and Blindness-Key Facts. Centre WM, editor.
6. Whitcher JP, Srinivasan M, Upadhyay MP (2001) Corneal blindness: a global perspective. Bull World Health Organ 79: 214–221.
7. London Fungal Research Trust (2011) How Common are fungal diseases? Available: www.fungalinfectedtissue.org/HowCommonAreFungalDiseases2.pdf.
8. Leal SM, Jr., Varechoon C, Cowden S, Cobb RA, Latge JP, et al. (2012) Fungal antioxidant pathways promote survival against neutrophils during infection. J Clin Invest 122: 2482–2498.
9. Wood ZA, Schroeder E, Robin Harris J, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32–40.
10. Winterbourne CC (2000) Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4: 278–286.
11. Schreit M, Biguell E, Krag J, Sahiba Y, Loss O, et al. (2007) Distinct roles for intracellular and extracellular siderophores during *Aspergillus fumigatus* infection. PLoS Pathog 3: 1193–1207.
12. Haas H, Eisenhle M, Turgeon BG (2008) Siderophores in fungal physiology and virulence. Annu Rev Phytopathol 46: 149–187.
13. Haas H (2012) Iron - A Key Nexus in the Virulence of *Aspergillus fumigatus*. Front Microbiol 3: 29.
14. Yasmin S, Alcazar-Fuoli L, Grundlinger M, Ponder BP, Cairns T, et al. (2012) Corynebacterium glutamicum regulates iron assimilation in the fungal pathogen *Aspergillus fumigatus*. Proc Natl Acad Sci U S A 109: E497–504.
15. Hartse MW, Muckenthaler MU, Galy B, Gamachella C (2010) Two to Tango: regulation of Mammalian iron metabolism. Cell Biol 39: 361–369.
16. Melise L, Willcox MD (2009) Role of lactoferrin in the tear film. Biochimie 91: 35–41.
17. Flockinger M, Haas H, Morschak P, Glasgow BJ, Redl B (2004) Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 48: 3367–3372.
18. Skarz EP (2010) The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 6: e1000949.
19. Anulic B, Cazalet C, Hayes GL, Metzler KD, Chizhovsky A (2012) Neutrophil function from mechanisms to disease. Annu Rev Immunol 30: 459–489.
20. Armitage AE, Edghills LA, Gileadi U, Cole S, Spotzwoode N, et al. (2011) HapX-mediated Hepcidin regulation by innate immune and infectious stimuli. Blood 118: 4129–4139.
21. Peyssonnaux C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, et al. (2006) HapX-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107: 3727–3732.
22. Gasel T, Nemeth E (2011) HapX-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107: 3727–3732.
23. Hartkeyesan RS, Leal SM, Jr., Pratima NV, Dharmalingam K, Geiser DM, et al. (2011) Expression of innate and adaptive immune mediators in human corneal tissue infected with *Aspergillus fumigatus*. J Infect Dis 204: 942–950.
24. Hider RC, Kong X (2010) Chemistry and biology of siderophores. Nat Prod Rep 27: 637–657.
25. Correnzi C, Strong RK (2012) Mammalian siderophores, siderophore-binding lipocalins, and the labile iron pool. J Biol Chem 287: 13524–13531.
26. Dartt DA (2011) Tear lipocalin: structure and function. Ocul Surf 9: 126–138.
27. Patric M, Haas H, Schreit M, Høbek A, Blatter M, et al. (2012) In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging. Nucl Med Biol 39: 361–369.
28. Schreit M, Biguell E, Krag J, Joesch C, Rogers T, et al. (2004) Siderophore biosynthesis but not reductive iron assimilation is essential for *Aspergillus fumigatus* virulence. J Exp Med 200: 1215–1219.
29. Schreit M, Beckmann N, Varga J, Heinemann T, Jacobsen ID, et al. (2010) HapX-mediated adaption to iron starvation is crucial for virulence of *Aspergillus fumigatus*. PLoS Pathog 6: e1000124.
30. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, et al. (2004) Lipocandin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432: 917–921.
33. Corsini A, Bellota S, Bartata R, Fumagalli R, Pavolleti R, et al. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84: 413–428.
34. Zamocky M, Koller F (1999) Understanding the structure and function of catalases: clues from molecular evolution and in vitro maturation. Prog Biophys Mol Biol 72: 19–66.
35. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, et al. (2005) Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 1: e30.
36. Gersuk GM, Underhill DM, Zhu L, Marr KA (2006) Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol 176: 3717–3724.
37. Manuel Berges JC, David Turra, Lukas Schafferer, Sandra Mathijs, Christoph Jochl, Pierre Cornelis, Josep Guarro, Hubertus Haas, Antonio Di Pietro (2012) HapX-Mediated Iron Homeostasis Is Essential for Rhizosphere Competence and Virulence of the Soilborne Pathogen Fusarium oxysporum. Plant Cell 24: 3895–3902.
38. Oide S, Moeder W, Kraussoff S, Gibson D, Haas H, et al. (2006) NPS6, encoding a nonribosomal peptide synthetase involved in siderophore-mediated iron metabolism, is a conserved virulence determinant of plant pathogenic ascomycetes. Plant Cell 18: 2836–2853.
39. Liu H, Gravelat FN, Chiang LY, Chen D, Vanier G, et al. (2010) Aspergillus fumigatus AcuM regulates both iron acquisition and gluconeogenesis. Mol Microbiol 78: 1030–1054.
40. Smith MEB, Lee NJ, Haney E, Carson S (2009) Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. Portland (OR).
41. Gersuk GM, Underhill DM, Zhu L, Marr KA (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEBS Microbiol Lett 262: 9–13.
42. Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W (2007) Antifungal activity of statins against Aspergillus species. Med Mycol 45: 589–593.
43. Nyland F, Koosheh S, Krizan K, Galgoczy I, Pesti M, et al. (2010) In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEBS Microbiol Lett 307: 175–184.
44. Wojnar P, Lechner M, Redl B (2003) Antisense down-regulation of lipocalin-interacting membrane receptor expression inhibits cellular internalization of lipocalin-1 in human NT2 cells. J Biol Chem 278: 16209–16215.
45. Wojnar P, Lechner M, Merschak P, Redl B (2001) Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display. J Biol Chem 276: 20266–20272.
46. Follard RJ, Kissner DM (1993) Purification of the isoforms of tear specific prealbumin. Curr Eye Res 12: 613–620.
47. Zarember KA, Sugui JA, Chang YC, Kwon-Chung KJ, Gallin JI (2007) Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J Immunol 178: 6367–6373.
48. Ma Y, Zhou T, Kong X, Hider RC (2012) Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19: 2816–2827.
49. Robins-Browne RM, Piptie JK (1985) Effects of iron and deferoxamine on infections with Yersinia enterocolitica. Infect Immun 47: 774–779.
50. Boelenc JR, van Rosst GF, Vergouwe PL, Verbanck JJ, de Vroey C, et al. (1988) The role of deferoxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 29: 261–266.
51. Windus DW, Stokes TJ, Julian BA, Feneis AZ (1987) Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 107: 678–680.
52. Christopher GW (1985) Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch Intern Med 145: 1908.
53. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
54. Altes A, Remacha AF, Sarda P, Sancho E, Sureda A, et al. (2004) Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 34: 505–509.
55. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
56. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
57. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
58. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
59. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
60. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
61. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
62. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
63. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
64. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
65. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
66. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.
67. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, et al. (2007) Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110: 1303–1306.